ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.00
0.00%
US Tech 100
19,926.80
0.13%
S&P 500
5,864.04
0.07%
US Dollar vs CAD
1.38116
0.06%
Bitcoin
65,802.38
-0.39%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Genenta Science SPA (GNTA) Share Price

Genenta Science SPA

Genenta Science SPA (GNTA)

NASDAQ
5.80
0.00
(0.00%)
Closed October 14 3:00PM
Delayed by 15 minutes
5.80
0.00
( 0.00% )
Pre Market: 8:15AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
5.80
Bid
2.51
Ask
7.00
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
105.658M
Previous Close
5.80
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
18,216,958
Dividend Yield
-
PE Ratio
-9.95
Earnings Per Share (EPS)
-0.58
Revenue
465k
Net Profit
-10.62M

About Genenta Science SPA

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's product under development includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affec... Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's product under development includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy. Show more

Sector
Health Practitioners, Nec
Industry
Health Practitioners, Nec
Website
www.genenta.com
Headquarters
Milan, Lombardy, Ita
Founded
-
Genenta Science SPA is listed in the Health Practitioners sector of the NASDAQ with ticker GNTA. The last closing price for Genenta Science was US$5.80. Over the last year, Genenta Science shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Genenta Science currently has 18,216,958 shares outstanding. The market capitalization of Genenta Science is US$105.66 million. Genenta Science has a price to earnings ratio (PE ratio) of -9.95.

Ask ADVFN Intelligence (AI)

GNTA Latest News

More News

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the...

October 02 2024
GlobeNewswire Inc.

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the...

May 06 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

February 12 2024
Edgar (US Regulatory)

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power...

February 08 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

October 20 2023
Edgar (US Regulatory)

Genenta to Present at Upcoming Scientific and Investor Conferences

MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power...

September 06 2023
GlobeNewswire Inc.

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science...

July 28 2023
GlobeNewswire Inc.

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of...

June 29 2023
GlobeNewswire Inc.

Genenta to Provide Update on Lead Product Temferon™

MILAN, Italy and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini, Ph.D., M.D., co-founder and Executive Scientific Board Chairman of Genenta Science S.p.A. (NASDAQ: GNTA), a...

May 16 2023
GlobeNewswire Inc.

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025Net exchange rate gain of €2.3 millionTax credit of €6.4 million MILAN...

April 26 2023
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
US$ 11.87
(0.00%)
605.97k
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 65.2884
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.15
(0.00%)
122
AACGATA Creativity Global
US$ 0.9999
(0.00%)
181
AALAmerican Airlines Group Inc
US$ 11.87
(0.00%)
605.97k
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 65.2884
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.15
(0.00%)
122
AACGATA Creativity Global
US$ 0.9999
(0.00%)
181
GRTSGritstone bio Inc
US$ 0.054
(0.00%)
140.35M
ZPTAZapata Computing Holdings Inc
US$ 0.077
(0.00%)
116.98M
DBGIDigital Brands Group Inc
US$ 0.1598
(0.00%)
30.79M
LIPOLipella Pharmaceuticals Inc
US$ 0.4087
(0.00%)
18.65M
ENVBEnveric Biosciences Inc
US$ 0.412
(0.00%)
14.48M

GNTA Discussion

View Posts
Awl416 Awl416 3 months ago
What leaked
👍️0
Monksdream Monksdream 6 months ago
GNTA under $3
👍️0
Luckypennyman Luckypennyman 2 years ago
FDA’s decision to grant Orphan Drug Designation to Temferon









glta
👍️0
makinezmoney makinezmoney 2 years ago
$GNTA: Just got a $15 PriceTarget upgrade.

From here $5, looks like its gonna be a nice ride up


GO $GNTA
👍️0
conix conix 3 years ago
Maxim starts Genenta Science at buy; PT $21

Stephen Kilmer

January 13, 2022

Maxim Group launched coverage of Genenta Science S.p.A (NASDAQ:GNTA) with a “buy” rating and $21 price target. The stock closed at $9.94 on Jan. 12.

Genenta is developing cancer therapeutics using an autologous ex-vivo, lentiviral-based gene therapy strategy.

The company initially is targeting unmethylated-MGMT glioblastoma multiforme (GBM) patients with its lead gene therapy, Temferon, which is currently being evaluated in a Phase 1/2 dose-escalation study. Data from the latter two cohorts are expected around the end of 2022.

“Tumor agnostic gene therapy, Temferon, can potentially be applied broadly to multiple cancer types because it is not tumor dependent,” writes analyst Naureen Quibria, Ph.D.

She said lentiviral-based gene therapy is a validated approach, with treatment approvals seen in Kymriah for acute lymphoblastic leukemia and diffuse large B-cell lymphoma, Zynteglo for ß-thalassemia, and Libmeldy for metachromatic leukodystrophy.

Genenta’s Temferon, has also demonstrated initial signals of efficacy in its Phase 1/2 clinical study in GBM, as well as robust activity in multiple tumor models in preclinical studies.

“Though the program is somewhat early, we believe the broad utility of the platform and potential durability of the approach support a ‘buy’ rating and our $21 price target,” Dr. Quibria said.
👍️0
asser_al7ob asser_al7ob 3 years ago
is this genta that we have before, it is coming back after years
👍️0
Phosphene Phosphene 3 years ago
Clinical-stage biotechnology company pioneering
the development of lentivirus-based first-in-class
gene and cell therapies in cancer.

Genenta uses gene-based cytokine delivery
to activate the immune system within the tumor,
providing a controlled, targeted and enduring anti-tumor response.

https://www.genenta.com/

TEM-GBM_001

👍️0

Your Recent History

NASDAQ
GNTA
Genenta Science
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved